Nature communications · 2018
FABP4 as a key determinant of metastatic potential of ovarian cancer.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gharpure Kshipra M, Pradeep Sunila, Sans Marta, Rupaimoole Rajesha, Ivan Cristina, Wu Sherry Y, Bayraktar Emine, Nagaraja Archana S, Mangala Lingegowda S, Zhang Xinna, Haemmerle Monika, Hu Wei, Rodriguez-Aguayo Cristian, McGuire Michael, Mak Celia Sze Ling, Chen Xiuhui, Tran Michelle A, Villar-Prados Alejandro, Pena Guillermo Armaiz, Kondetimmanahalli Ragini, Nini Ryan, Koppula Pranavi, Ram Prahlad, Liu Jinsong, Lopez-Berestein Gabriel, Baggerly Keith, S Eberlin Livia, Sood Anil K
Аннотация
The standard treatment for high-grade serous ovarian cancer is primary debulking surgery followed by chemotherapy. The extent of metastasis and invasive potential of lesions can influence the outcome of these primary surgeries. Here, we explored the underlying mechanisms that could increase metastatic potential in ovarian cancer. We discovered that FABP4 (fatty acid binding protein) can substantially increase the metastatic potential of cancer cells. We also found that miR-409-3p regulates FABP4 in ovarian cancer cells and that hypoxia decreases miR-409-3p levels. Treatment with DOPC nanoliposomes containing either miR-409-3p mimic or FABP4 siRNA inhibited tumor progression in mouse models. With RPPA and metabolite arrays, we found that FABP4 regulates pathways associated with metastasis and affects metabolic pathways in ovarian cancer cells. Collectively, these findings demonstrate that FABP4 is functionally responsible for aggressive patterns of disease that likely contribute to poor prognosis in ovarian cancer.